ABVX Should I Buy

• Buy now: Setup favors a near-term rebound (RSI ~38 near oversold, momentum bearish but improving) while Wall St targets imply meaningful upside from ~$113.
• Sentiment supports upside: Options positioning is call-leaning (low put/call ratios) with unusually high volume, consistent with bullish speculation into future clinical catalysts.
• Catalyst-driven profile: The stock’s next major value inflection is the Phase 3 UC maintenance readout (2Q26), with additional Crohn’s data later in 2026.

Intellectia Proprietary Trading Signals

• AI Stock Picker: no signal on given stock today.
• SwingMax: No signal on given stock recently.

• Price ~$113 is below pivot 116.726, suggesting the stock is trading under a key near-term balance point.
• Support/Resistance: S1 ~109.682 (nearby downside level), S2 ~105.33; resistance R1 ~123.77 then R2 ~128.122.
• MACD histogram -1.056 and below zero = bearish trend, but negatively contracting = downside momentum is fading (often a pre-bounce condition).
• RSI(6) 37.9: weak/near-oversold area rather than overbought—more consistent with sell pressure potentially getting exhausted.
• Moving averages converging: consolidation/transition phase (a break back above pivot would improve the trend picture).